FDA Alerts
FDA Drug Safety Communication: Chantix Heart Risk
The US Food and Drug Administration (FDA) is notifying the public that the smoking cessation aid Chantix (varenicline) may be associated with a small, increased risk of certain cardiovascular adverse events in patients who have cardiovascular disease.
FDA Safety Communication: Chantix
The U.S. Food and Drug Administration (FDA) has reviewed the results from two FDA-sponsored epidemiological studies that evaluated the risk of neuropsychiatric adverse events associated with the smoking cessation drug Chantix ( varenicline ).
FDA: Chantix (varenicline) May Increase Cardiovascular Risk
The U.S. Food and Drug Administration (FDA) is notifying the public that the smoking cessation aid Chantix ( varenicline ) may be associated with a small, increased risk of certain cardiovascular adverse events in patients who have cardiovascular disease.